Table 3.

Characteristics of the patients infected between day 30 and day 240 post-vaccination.

Patient	Gender	Age Years	Anti-S IgG (BAU/mL)	Days between 2nd Dose and Positive Test	Days between 2nd Dose and Anti-S IgG Measurement	Days between Anti-S IgG Measurement and Positive Test	Anti-SARS-CoV-2 Test (Variant)
Patient 1	Female	63	964.24	66	40	26	PCR test (B.1.1.7)
Patient 2	Female	62	3909.64	170	31	139	PCR test
Patient 3	Female	26	2121.22	183	31	152	Antigen test
Patient 4	Female	54	4332.11	185	31	154	PCR test (B.1.617)
Rest of BNT162b2 volunteers	Male n = 11 Female n = 67	46 [22–65]	1939.42	-	32	-	-

For each patient are listed the gender, age, Anti-S IgG levels and days concerning the vaccination, IgG measurement and SARS-CoV-2 testing. We calculated the mean age and anti-S IgG for the rest of the volunteers vaccinated with BNT162b2.